NASDAQ
No price data available for this timeframe.
Fate Therapeutics, Inc. (FATE) has a price/sales ratio of 17.56x as of Friday, May 22, 2026. This represents a 45.53% decrease compared to its 12-month average of 32.24x. The price-to-sales ratio evaluates a company's stock price relative to its revenue, useful for valuing companies with little or no earnings.